Association of bile acid composition with synthetic pathways and efficacy of bezafibrate in cholestatic liver disease
Clinical and Molecular Hepatology · 2025
DOI: 10.3350/cmh.2025.0575 ↗Kurz gefasst
Fachartikel in der Zeitschrift Clinical and Molecular Hepatology, 2025. Verfasst von Manami Iida und 8 weiteren Autor:innen. Beteiligte Einrichtung: Research Division, Chugai Pharmaceutical Co., Ltd., Kanagawa, Japan. Hauptthemen laut MEDLINE: Bezafibrate, Bile Acids and Salts, Liver Cirrhosis, Biliary. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 23 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 3.0). Gefördert von: Chugai Pharmaceutical Co., Ltd..
Abstract (Originalsprache)
Background/Aims: Bezafibrate (BZF), a dual peroxisome proliferator-activated receptor/pregnane X receptor agonist, has demonstrated efficacy in combination with ursodeoxycholic acid (UDCA) for primary biliary cholangitis (PBC) and primary sclerosing cholangitis (PSC). Although one of the therapeutic effects of BZF is suppression of bile acid synthesis, its specific impact on bile acid synthesis pathways has not been thoroughly explored. This study investigated bile acid profiles, synthesis intermediates, and their associations with liver biochemistries in patients with PBC and PSC, and evaluated the impact of BZF treatment on these associations.
Methods
We enrolled 30 patients with PBC, 10 with PSC, and 30 control subjects. We measured total bile acids, bile acid components, plasma levels of 7α-hydroxycholesterol (7α-OH-C), 7α-hydroxy-4-cholesten-3-one (C4), and 27-hydroxycholesterol (27-OH-C) to assess the classic and alternative bile acid synthesis pathways and analyzed the association with liver biochemistries with and without BZF treatment.
Results
Total bile acid levels were elevated in PBC and PSC compared to controls, correlating significantly with liver biochemistries. BZF treatment significantly suppressed the classic pathway, as evidenced by reduced 7α-OH-C and C4 levels. However, 27-OH-C levels, possibly reflecting the alternative pathway activity, were not reduced in those with elevated liver biochemistries despite BZF treatment, suggesting incomplete suppression of alternative pathway in patients with suboptimal BZF response.
Conclusions
These findings indicate that while BZF effectively suppresses the classic pathway, alternative pathway activity may compromise its therapeutic efficacy in treatment-resistant cases, highlighting the need for novel therapies inhibiting the alternative pathway in patients with inadequate response to BZF.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Research Division, Chugai Pharmaceutical Co., Ltd., Kanagawa, Japan.
- Chugai Research Institute for Medical Science, Inc., Kanagawa, Japan.
- Translational Research Division, Chugai Pharmaceutical Co., Ltd., Tokyo, Japan.
- Department of Medicine, Teikyo University School of Medicine, Tokyo, Japan.
- Division of Gastroenterology and Hepatology, Department of Internal Medicine, Tokyo Medical University Ibaraki Medical Center, Ibaraki, Japan.
Förderung
- Chugai Pharmaceutical Co., Ltd.
Zitieren
APA
Iida, M., Higashida, A., Ohtomo, S., Takeuchi, A., Miura, R., Asaoka, Y., Horiba, N., Honda, A., & Tanaka, A. (2025). Association of bile acid composition with synthetic pathways and efficacy of bezafibrate in cholestatic liver disease. Clinical and Molecular Hepatology. https://doi.org/10.3350/cmh.2025.0575
Vancouver
Iida M, Higashida A, Ohtomo S, Takeuchi A, Miura R, Asaoka Y, et al. Association of bile acid composition with synthetic pathways and efficacy of bezafibrate in cholestatic liver disease. Clinical and Molecular Hepatology. 2025. doi:10.3350/cmh.2025.0575
BibTeX
@article{Iida2025,
author = {Iida, Manami and Higashida, Atsuko and Ohtomo, Shuichi and Takeuchi, Akihito and Miura, Ryo and Asaoka, Yoshinari and Horiba, Naoshi and Honda, Akira and Tanaka, Atsushi},
title = {Association of bile acid composition with synthetic pathways and efficacy of bezafibrate in cholestatic liver disease},
journal = {Clinical and Molecular Hepatology},
year = {2025},
doi = {10.3350/cmh.2025.0575}
}
EUVIMED